Search results for "Guidelines as Topic"

showing 10 items of 372 documents

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

2015

Accepted Article

AllergyAllergyMedical InformaticSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOWORLD-HEALTH-ORGANIZATIONReviewComorbidityWeb BrowserHealth informatics:Medicina Clínica [Ciências Médicas]ARIA; ICT; MACVIA-LR; allergic rhinitis; asthma; clinical decision support system; conjunctivitis; visual analogue scalevisual analogue scaleQUALITY-OF-LIFEconjunctivitisMedicineImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSRhinitisClinical Trials as TopicCLIMATE-CHANGE[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAllergenHealth PolicyDisease ManagementRANDOMIZED CONTROLLED-TRIAL3. Good healthCHRONIC RESPIRATORY-DISEASESclinical decision support systemINTEGRATED CARE PATHWAYS1107 ImmunologyVISUAL ANALOG SCALESPractice Guidelines as TopicMedical emergencyallergic rhinitiLife Sciences & BiomedicineHumanEUROPEAN INNOVATION PARTNERSHIPImmunologyClinical Decision-MakingSocio-culturaleReproducibility of Resultallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web Browser; Immunology and Allergy; ImmunologyInformation and communications technologyClinical decision support systemMACVIA-LRQuality of life (healthcare)AllergicARIA; Information and communications technology; MACVIA-LR; allergic rhinitis; asthmaJournal ArticleHumansCiências Médicas::Medicina ClínicaAsthmaScience & Technologyallergic rhinitisARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAReproducibility of ResultsGuidelineBiomarkerta3121Allergensasthmamedicine.diseaseRhinitis AllergicIntegrated careHealth PlanningPOLLEN COUNTSICTallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web BrowserImmunologybusinessDECISION-SUPPORT-SYSTEMSBiomarkersMedical Informatics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations.

2015

The neurolytic blocks of sympathetic pathways, including celiac plexus block (CPB) and superior hypogastric plexus block (SHPB) , have been used for years. The aim of this review was to assess the evidence to support the performance of sympathetic blocks in cancer patients with abdominal visceral pain. Only comparison studies were included. All data from the eligible trials were analyzed using the GRADE system. Twenty-seven controlled studies were considered. CPB, regardless of the technique used, improved analgesia and/or decrease opioid consumption, and decreased opioid-induced adverse effects in comparison with a conventional analgesic treatment. In one study patients treated with superi…

AnalgesicPainOpioidmedicine.nerveSympathetic blockSuperior hypogastric plexusMedicineHumansPain ManagementCancer painAdverse effectAutonomic Nerve BlockIntention-to-treat analysisbusiness.industryCeliac plexus blockVisceral painHematologyAnalgesics OpioidEuropeOncologySample size determinationAnesthesiaAbdominal NeoplasmsPractice Guidelines as Topicmedicine.symptomGeriatrics and GerontologybusinessCancer painSuperior hypogastric plexus blockAutonomic Nerve BlockCritical reviews in oncology/hematology
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

Choosing the Right Antifungal Agent in ICU Patients

2019

Fungi are responsible for around 20% of microbiologically documented infections in intensive care units (ICU). In the last decade, the incidence of invasive fungal infections (IFI), including candidemia, has increased steadily because of increased numbers of both immunocompromised and ICU patients. To improve the outcomes of patients with IFI, intensivists need to be aware of the inherent challenges. This narrative review summarizes the features of routinely used treatments directed against IFI in non-neutropenic ICU patients, which include three classes of antifungals: polyenes, azoles, and echinocandins. ICU patients' pathophysiological changes are responsible for deep changes in the phar…

AzolesAntifungal AgentsReviewKidney Function TestsInvasive aspergillosiEchinocandins0302 clinical medicineLiver Function Tests[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesMedicineDrug InteractionsPharmacology (medical)030212 general & internal medicineComputingMilieux_MISCELLANEOUSmedia_common[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesIncidenceIncidence (epidemiology)CandidiasisGeneral MedicineSerum concentrationIntensive care patients3. Good healthIntensive Care UnitsPractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCandidiasiNarrative reviewDrug MonitoringInvasive fungi infectionAntifungalDrugmedicine.medical_specialtyIcu patientsmedicine.drug_classmedia_common.quotation_subjectPharmacokineticPolyenesImmunocompromised Host03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIntensive careHumansPharmacokinetics[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care medicineIntensive care patient030306 microbiologybusiness.industry[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyInvasive aspergillosisLiver functionbusinessPractical guidelinesInvasive Fungal InfectionsAdvances in Therapy
researchProduct

Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HERO…

2010

J Clin Hypertens (Greenwich). The Efectividad de un Programa de Intervencion en el Control de la Presion Arterial de los Hipertensos en Riesgo de Desarrollar Insuficiencia Cardiaca (HEROIC) study was designed to assess whether an educational program for primary care physicians could improve blood pressure (BP) control in hypertensive patients at high risk for developing heart failure. The program contained a combination of educational training (live group sessions or online training) and information feedback. Two hundred twenty-six physicians completed the program and provided valid data in 2489 patients before and 2168 after 1 year. There was a small but significant reduction of −1.1 mm Hg…

Blood pressure controlMaleRiskmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDeveloping heartBlood PressurePrimary carePhysiciansInternal MedicineMedicineHumansProspective StudiesPractice Patterns Physicians'Intensive care medicineAntihypertensive AgentsAgedHeart FailurePrimary Health Carebusiness.industrymedicine.diseaseOriginal PapersBlood pressureCross-Sectional StudiesTreatment OutcomeSpainHeart failureEmergency medicineHypertensionPractice Guidelines as TopicEducation Medical ContinuingFemaleCardiology and Cardiovascular MedicinebusinessInformation feedbackEducational programEducational trainingJournal of clinical hypertension (Greenwich, Conn.)
researchProduct

Interdisciplinary consensus on the uses and technique of MR-guided vacuum-assisted breast biopsy (VAB): results of a European consensus meeting.

2009

Abstract Purpose Quality assurance of MR-guided vacuum-assisted breast biopsy (VAB). Method A consensus was achieved based on the existing literature and experience of an interdisciplinary group comprising European specialists in breast imaging and VAB. Results Full imaging work-up must be completed according to existing standards before an indication for MR-guided VAB is established. The procedure should be reserved for lesions demonstrable by MRI alone. Acquisition of >24 cores (11-Gauge) should be routinely attempted, with the intention of sufficiently removing small lesions for accurate diagnosis. Following biopsy the patient should be re-imaged to demonstrate the biopsy site and its pr…

Breast biopsymedicine.medical_specialtymedicine.diagnostic_testBreast imagingbusiness.industryBiopsy NeedleMEDLINEGeneral MedicineAuditMagnetic Resonance ImagingSurgeryEuropeBiopsy SiteSurgery Computer-AssistedBiopsyVacuum-assisted breast biopsyPractice Guidelines as TopicmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsSampling (medicine)businessEuropean journal of radiology
researchProduct

Overall asthma control: the relationship between current control and future risk.

2009

Background Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler ∗ ∗Symbicort SMART and Turbuhaler are trademarks owned by AstraZeneca. Neither the Symbicort SMART posology nor the dry powder formulation Turbuhaler are currently approved in the United States.) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods The perc…

BudesonideAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyYoung AdultAdrenal Cortex HormonesInternal medicineFormoterol FumarateSurveys and QuestionnairesAdministration InhalationmedicineImmunology and AllergyBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsRisk factorBudesonideChildAsthmaAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overInhalationbusiness.industryAdrenergic beta-AgonistsMiddle Agedmedicine.diseaseAsthmaMarkov ChainsDrug CombinationsAsthma Control QuestionnaireEthanolaminesChild PreschoolPractice Guidelines as TopicPhysical therapyFormoterol FumarateFemaleFormoterolbusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct